| Drug General Information |
| Drug ID |
D0F5HB
|
| Former ID |
DCL000996
|
| Drug Name |
Sotrastaurin acetate
|
| Drug Type |
Small molecular drug
|
| Indication |
Renal transplantation [ICD9: 279.5; ICD10:D89.8]
|
Phase 2 |
[1]
|
|---|
| Company |
Novartis
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C27H26N6O4
|
| Canonical SMILES |
CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O<br />)C5=CNC6=CC=CC=C65
|
| InChI |
1S/C25H22N6O2.C2H4O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18;1-2(3)4/h2-9,14,26H,10-13H2,1H3,(H,29,32,33);1H3,(H,3,4)
|
| InChIKey |
RVEUYBMXVVDLFO-UHFFFAOYSA-N
|
| CAS Number |
CAS 908351-31-5
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Protein kinase C, theta type |
Target Info |
Inhibitor |
[1]
|
|---|
| Protein kinase C, beta type |
Target Info |
Inhibitor |
[1]
|
| Protein kinase C, alpha type |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Adipocytokine signaling pathway
|
|
Measleshsa04010:MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
Wnt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Natural killer cell mediated cytotoxicity
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Leukocyte transendothelial migration
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Long-term depression
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Melanogenesis
|
|
Thyroid hormone synthesis
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Aldosterone-regulated sodium reabsorption
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Salivary secretion
|
|
Gastric acid secretion
|
|
Pancreatic secretion
|
|
Carbohydrate digestion and absorption
|
|
Amphetamine addiction
|
|
Morphine addiction
|
|
Vibrio cholerae infection
|
|
Leishmaniasis
|
|
African trypanosomiasis
|
|
Amoebiasis
|
|
Hepatitis B
|
|
Influenza A
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Non-small cell lung cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Pathogenic Escherichia coli infection
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Wnt signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Histamine H1 receptor mediated signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Thyrotropin-releasing hormone receptor signaling pathway
|
|
CCKR signaling map STP00003:Alzheimer disease-amyloid secretase pathway
|
|
B cell activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
CCKR signaling map STP00002:Alpha adrenergic receptor signaling pathway
|
|
PDGF signaling pathway
|
|
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
TCR signaling in naï
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Downstream signaling in naï
|
|
Fc-epsilon receptor I signaling in mast cells
|
|
IL2-mediated signaling events
|
|
Ras signaling in the CD4+ TCR pathway
|
|
JNK signaling in the CD4+ TCR pathway
|
|
Regulation of Ras family activation
|
|
Endothelins
|
|
Canonical NF-kappaB pathway
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
mTOR signaling pathway
|
|
ErbB1 downstream signaling
|
|
Syndecan-4-mediated signaling events
|
|
ATF-2 transcription factor network
|
|
PDGFR-beta signaling pathway
|
|
Retinoic acid receptors-mediated signaling
|
|
IL8- and CXCR2-mediated signaling events
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
a6b1 and a6b4 Integrin signaling
|
|
IL8- and CXCR1-mediated signaling events
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Activation of PKC through G protein coupled receptor
|
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
|
Effects of PIP2 hydrolysis
|
|
Inactivation, recovery and regulation of the phototransduction cascade
|
|
FCERI mediated NF-kB activation
|
|
G alpha (z) signalling eventsR-HSA-114516:Disinhibition of SNARE formation
|
|
Activation of NF-kappaB in B cells
|
|
Trafficking of GluR2-containing AMPA receptors
|
|
G alpha (z) signalling events
|
|
Depolymerisation of the Nuclear Lamina
|
|
WNT5A-dependent internalization of FZD4
|
|
VEGFR2 mediated cell proliferation
|
|
Response to elevated platelet cytosolic Ca2+R-HSA-111933:Calmodulin induced events
|
|
Disinhibition of SNARE formation
|
|
Regulation of KIT signaling
|
|
EGFR Transactivation by Gastrin
|
|
Syndecan interactions
|
|
Acetylcholine regulates insulin secretion
|
|
Ca2+ pathway
|
|
HuR (ELAVL1) binds and stabilizes mRNA
|
|
Response to elevated platelet cytosolic Ca2+
|
|
WikiPathways
|
TCR Signaling Pathway
|
|
Calcium Regulation in the Cardiac Cell
|
|
Insulin Signaling
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Corticotropin-releasing hormone
|
|
Signaling Pathways in Glioblastoma
|
|
miRs in Muscle Cell Differentiation
|
|
TCR signaling
|
|
Netrin-1 signaling
|
|
GPCR downstream signaling
|
|
Effects of PIP2 hydrolysis
|
|
Apoptotic execution phaseWP536:Calcium Regulation in the Cardiac Cell
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Kit receptor signaling pathway
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Oncostatin M Signaling Pathway
|
|
AGE/RAGE pathway
|
|
B Cell Receptor Signaling Pathway
|
|
Response to elevated platelet cytosolic Ca2+
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Physiological and Pathological Hypertrophy of the HeartWP673:ErbB Signaling Pathway
|
|
Transcriptional activation by NRF2
|
|
Human Complement System
|
|
Cardiac Hypertrophic Response
|
|
Syndecan interactions
|
|
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
|
|
Signaling by SCF-KIT
|
|
DAG and IP3 signaling
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Pathogenic Escherichia coli infection
|
|
Endothelin Pathways
|
|
Regulation of Microtubule Cytoskeleton
|
|
FSH signaling pathway
|
|
Opioid Signalling
|
|
Integration of energy metabolism
|
|
TOR Signaling
|
| References |
| REF 1 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. |
|---|
